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In addition to accumulating amyloid  peptide (A42), el-
evation of ceramide and mitochondrial damage is observed 
in Alzheimer’s disease (AD) (1, 2). Our laboratory discov-
ered that incubation of astrocytes with A42 activates neutral 
SMase 2 (nSMase2), a bona fide signaling enzyme generating 
ceramide from sphingomyelin (3, 4). While examining the 
effect of A42 on astrocytes in time-lapse imaging, we discov-
ered that mitochondria in nSMase2-deficient astrocytes were 
more resistant to A42-induced damage, but they also moved 
more rapidly than those in wild-type astrocytes. nSMase2 has 
been shown to shuttle between the plasma membrane and 
Golgi and it is activated by mitochondrial lipids (5–8), 
prompting us to test the effect of nSMase2-generated ce-
ramide on mitochondrial motility and function.
Ceramide is a sphingolipid the concentration of which is 
less than 1 mol% (compared with approximately 10 mol% 
Abstract We reported that amyloid  peptide (A42) acti-
vated neutral SMase 2 (nSMase2), thereby increasing the 
concentration of the sphingolipid ceramide in astrocytes. 
Here, we show that A42 induced mitochondrial fragmenta-
tion in wild-type astrocytes, but not in nSMase2-deficient cells 
or astrocytes treated with fumonisin B1 (FB1), an inhibitor 
of ceramide synthases. Unexpectedly, ceramide depletion 
was concurrent with rapid movements of mitochondria, indi-
cating an unknown function of ceramide for mitochondria. 
Using immunocytochemistry and super-resolution micros-
copy, we detected ceramide-enriched and mitochondria- 
associated membranes (CEMAMs) that were codistributed 
with microtubules. Interaction of ceramide with tubulin 
was confirmed by cross-linking to N-[9-(3-pent-4-ynyl-3-H- 
diazirine-3-yl)-nonanoyl]-D-erythro-sphingosine (pacFACer), 
a bifunctional ceramide analog, and binding of tubulin to 
ceramide-linked agarose beads. Ceramide-associated tubulin 
(CAT) translocated from the perinuclear region to periph-
eral CEMAMs and mitochondria, which was prevented in 
nSMase2-deficient or FB1-treated astrocytes. Proximity liga-
tion and coimmunoprecipitation assays showed that ce-
ramide depletion reduced association of tubulin with 
voltage-dependent anion channel 1 (VDAC1), an interaction 
known to block mitochondrial ADP/ATP transport. Ceramide-
depleted astrocytes contained higher levels of ATP, sug-
gesting that ceramide-induced CAT formation leads to 
VDAC1 closure, thereby reducing mitochondrial ATP re-
lease, and potentially motility and resistance to A42.  Our 
data also indicate that inhibiting ceramide generation may 
protect mitochondria in Alzheimer’s disease.—Kong, J-N., 
Z. Zhu, Y. Itokazu, G. Wang, M. B. Dinkins, L. Zhong, H-P. Lin,
A. Elsherbini, S. Leanhart, X. Jiang, H. Qin, W. Zhi, S. D.
Spassieva, and E. Bieberich. Novel function of ceramide for
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sphingomyelin) in cellular membranes (9). It is mainly syn-
thesized in the endoplasmic reticulum (ER) by ceramide 
synthases (CerSs), which attach a variety of fatty acid resi-
dues to long chain bases, such as sphingosine and dihydro-
sphingosine, or by hydrolysis of sphingomyelin that is 
catalyzed by different SMases in distinct cellular com-
partments, such as the plasma membrane, lysosomes, the 
Golgi apparatus, and mitochondria (10–15). Increase of 
ceramide levels through upregulation of CerSs or SMases 
leads to induction of apoptosis and other cell signaling 
pathways critical for cell death, senescence, autophagy, or 
cell cycle arrest. We and others showed that the localized 
generation or distribution of ceramide in ceramide micro-
domains (rafts) or more extended ceramide-enriched 
compartments (CECs) may have additional cellular func-
tions of ceramide (16–23). Instrumental to our studies was 
the generation of a ceramide-specific antibody originally 
developed in our laboratory (24). This antibody has been 
shared with several independent laboratories to reliably de-
tect and visualize ceramide in cells and tissues and it is the 
only antibody applicable to super-resolution microscopy 
using stochastic optical reconstruction microscopy (STORM) 
(3, 18, 25–27). In addition to the ceramide-specific anti-
body, we developed a novel imaging protocol based on 
cross-linking of photoactivatable ceramide analogs {bifunc-
tional ceramide or N-[9-(3-pent-4-ynyl-3-H-diazirine-3-yl)-
nonanoyl]-D-erythro-sphingosine (pacFACer)} that can be 
derivatized with fluorophores or biotin using click chemis-
try. We demonstrated that these ceramide analogs are dis-
tributed to CECs and can be used to visualize and identify 
proteins binding to ceramide (19).
Previous studies showed that ceramide analogs were 
cross-linked or bound to tubulin (28, 29). We showed that 
tubulin was coimmunoprecipitated when pulling down 
intracellular vesicles using anti-ceramide IgG (20). These 
studies suggested that ceramide may bind to free tubulin 
dispersed in the cytosol, or to tubulin embedded into mi-
crotubules or associated with cellular membranes (mem-
brane tubulin). Membrane tubulin has been detected in 
the plasma membrane, but also in other compartments 
and organelles, such as the ER and mitochondria (30, 31). 
Tubulin has been suggested to bind to lipids in the cyto-
solic leaflet of the outer mitochondrial membrane (OMM) 
to initiate closure of voltage-dependent anion channel 1 
(VDAC1) (32–34), one of the key channels mediating ADP/
ATP transport between mitochondria and the cytosol.
Malfunction of mitochondria and dysregulated VDAC1 
have been implicated in many neurodegenerative diseases, 
including AD, Huntington’s disease, Parkinson’s disease, 
amyotrophic lateral sclerosis, and frontotemporal demen-
tia (35–42). In AD, A has been shown to bind to VDAC1, 
reduce ATP levels, and cause mitochondrial fragmenta-
tion during early stages of the disease (35, 43, 44). VDAC1 
downregulation has been reported to reduce cellular ATP 
levels and induce mitochondrial fragmentation (45, 46), 
eventually leading to neurodegeneration. In astrocytes, 
VDAC1 is critical for secretion of ATP, a gliotransmitter 
regulating synaptic plasticity and neuronal function (47–50). 
Most recently, VDAC1 closure by tubulin has been suggested 
to be critical for the Warburg effect, a metabolic switch 
from mitochondria-mediated oxidative phosphorylation to 
glycolysis for ATP production, often observed in cancer 
cells (51–53).
While assays with mitochondria showed that lipid-tubu-
lin interaction is important for tubulin-mediated VDAC1 
closure (52, 54–56), the role of ceramide in this regulation 
has not been investigated yet. In addition, there is only lit-
tle information available on the role of lipid-tubulin inter-
action for the function of mitochondria in intact cells. 
Studies from several laboratories found that ceramide is 
enriched in mitochondria and mitochondria-associated 
membranes (MAMs) (57, 58). MAMs are a subcompart-
ment of the ER that forms contact sites with mitochondria 
and takes part in the cross-talk between mitochondria and 
microtubules. While CerSs and nSMases have been shown 
to generate ceramide in mitochondria involved in induc-
ing apoptosis (59–62), it is not known whether ceramide 
regulates the function of MAMs and whether this in-
volves ceramide-associated tubulin (CAT) and its effect on 
VDAC1.
To test a potential role of CAT located at MAMs for the 
regulation of mitochondria, we used several complemen-
tary experimental approaches: 1) determining the effect 
of ceramide depletion by nSMase2 deficiency or the CerS 
inhibitor, fumonisin B1 (FB1), on mitochondrial mor-
phology and motility; 2) confocal microscopy and STORM 
using anti-ceramide IgG for testing the association of ce-
ramide with mitochondria and microtubules; 3) cross-link-
ing of pacFACer and binding to ceramide agarose beads to 
test ceramide association to tubulin; 4) proximity ligation 
assays (PLAs) and coimmunoprecipitation assays to quan-
tify CAT and CAT-VDAC1 complexes in primary cultured 
astrocytes and test the effect of ceramide depletion on 
complex formation; and 5) measurement of ATP levels in 
nSMase2-deficient or FB1-treated astrocytes to determine 
the effect of ceramide depletion on CAT-induced VDAC1 
closure. Our results suggest that CAT localized at ce-
ramide-enriched MAMs (CEMAMs) induces interaction of 
tubulin with VDAC1, a novel regulatory mechanism criti-
cal for mitochondria and, potentially, pathophysiology in 
AD.
MATERIALS AND METHODS
Reagents
MitoTracker Red CM-H2Xros (M-7513), Duolink PLA probe 
anti-rabbit plus (DUO92002), Duolink PLA probe anti-mouse 
minus (DUO92004), Duolink PLA probe anti-goat minus 
(DUO92006), Duolink detection reagent red (DUO92008), Duo-
link detection reagent green (DUO92014), Alexa Fluor 647 azide 
(A10277), Invitrogen Click-iT cell reaction buffer kit (C10269), 
and Click-iT protein reaction buffer kit (C10276) were purchased 
from Thermo Fisher Scientific (West Columbia, SC); CytoPainter 
mitochondrial staining kit-green fluorescence (ab112143) and 
ATP photometric/fluorimetric assay (ab83355) were from Abcam 
(Cambridge, MA); pacFACer was obtained from Avanti Polar Lipids 
(Alabaster, AL); TAMRA-azide-desthiobiotin (1110-5) was from 
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Click Chemistry Tools (Scottsdale, AZ); cyanine 7.5 azide (A6030) 
was purchased from Lumiprobe (Hallandale Beach, FL); 2-mer-
captoethanol (636890), cysteamine (30070), glucose oxidase from 
Aspergillus niger type VII (G2133-250 KU), and catalase from bovine 
liver (C40) were purchased from Sigma-Aldrich (St. Louis, MO). 
A1-42 was from Anaspec (Freemont, CA) dissolved in 1% ammo-
nia and diluted to 1 mg/ml and neutralized in PBS prior to use.
Preparation and treatment of primary astrocytes cultures
All experiments were carried out according to an Animal Use 
Protocol approved by the Institutional Animal Care and Use Com-
mittee at Augusta University and the University of Kentucky. Pri-
mary glial cells were isolated from brains of P0-P1 (day at birth or 
next day) C57BL/6 wild-type or nSMase2-deficient fro/fro mouse 
pups. Brains were dissociated in PBS containing 0.1 M glucose, 
passed through a 40 m filter, and plated in T-25 flasks in DMEM 
(Life Technologies, Grand Island, NY) supplemented with 10% 
fetal bovine serum, and 1% penicillin/streptomycin solution at 
37°C in a humidified atmosphere containing 5% CO2. After 7 
days, adherent cells were passed to 24-well plates containing un-
coated glass coverslips and cultured in DMEM as described above.
Immunocytochemistry and confocal microscopy
Cells were fixed with 4% p-formaldehyde/0.5% glutaralde-
hyde/PBS for 15 min and then permeabilized by incubation with 
0.2% Triton X-100 in PBS for 5 min at room temperature. Non-
specific binding sites were blocked with 3% ovalbumin/PBS for 
1 h at 37°C. The primary antibodies used were: anti-acetylated tu-
bulin mouse IgG (1:3,000, Sigma-Aldrich, clone 6-1113-1, T6793), 
anti-ceramide rabbit IgG (1:100, our laboratory) (20, 24), anti-
ceramide mouse IgM (1:100, MAB0014, Glycobiotech GmbH), 
anti-sigma receptor 1 goat IgG (1:200, Santa Cruz, clone S-18, 
sc-22948), anti--tubulin mouse monoclonal IgG (1:200, Santa 
Cruz, clone B-7, sc-5286), anti--tubulin goat IgG (1:200, Santa 
Cruz, clone N-20, sc-9935), anti--tubulin mouse monoclonal 
IgG (1:200, Santa Cruz, clone D-10, sc-5274), anti-calnexin goat 
IgG (1:200, Santa Cruz, sc-6465), anti-Tom 20 rabbit IgG (1:200, 
Santa Cruz, sc-11415), anti-tubb4 mouse IgG (1:200, Invitrogen, 
1-20247), anti-IP3 receptor mouse IgG (1:200, University of Cali-
fornia Davis/National Institutes of Health NeuroMab facility,
clone L2418), anti-VDAC1 rabbit IgG (1:500, Abcam, ab15895).
Secondary antibodies (Alexa Fluor 546-conjugated donkey anti-
rabbit IgG, Cy5-conjugated donkey anti-mouse IgM -chain spe-
cific, Alexa Fluor 647-conjugated goat anti-mouse IgG -chain
specific (all Jackson ImmunoResearch, West Grove, PA) were di-
luted 1:300 in 0.1% ovalbumin/PBS and samples incubated for
2 h at 37°C. After washing, coverslips were mounted using Fluoro-
shield supplemented with DAPI (Sigma-Aldrich) to visualize the
nuclei. Confocal fluorescence microscopy was performed using a
Zeiss LSM780 upright confocal laser scanning microscope (Zeiss,
Jena, Germany) equipped with a two-photon argon laser at 488,
543, or 633 nm. Images were processed using Zeiss Zen software.
Image analysis of colocalization and motility
Randomly chosen sections of images (blinded) were analyzed 
using the colocalization 2 function in Fiji/Image J software. The 
degree of colocalization was assessed by calculation of the Pearson’s 
correlation coefficient for two fluorescence channels in overlays, 
as previously described (63). A similar technique was used for de-
termining motility of mitochondria using overlays of two consecu-
tive time frames assigned to two different fluorescence channels. 
Motility was inversely correlated to the Pearson’s correlation coef-
ficient in the overlay. All of the data were collected from three 
independent cell cultures using five randomly selected areas per 
culture for determination of mitochondrial motility.
NSTORM
Cells were fixed and subjected to immunocytochemistry using 
primary antibodies, as described for confocal microscopy. To en-
sure the optical properties required for STORM, Atto 488 anti-
rabbit and Alexa Fluor 647 anti-mouse antibodies were used as 
secondary antibodies. Samples were immersed in buffers pre-
pared as follows: buffer A, 10 mM Tris (pH 8.0) + 50 mM NaCl; 
buffer B, 50 mM Tris (pH 8.0) + 10 mM NaCl + 10% glucose; 
GLOX solution (250 l), 14 mg glucose oxidase (Sigma-Aldrich) 
+ 50 l catalase from bovine liver-lyophilized powder (17 mg/ml)
(Sigma-Aldrich) + 200 l buffer A. Buffers A and B were freshly
prepared, vortexed, and spun down at 13,000 rpm. Only the su-
pernatant was used for preparing the NSTORM imaging buffer
by adding 7 l GLOX and 70 l 1 M cysteamine (MEA) (Sigma-
Aldrich) to 620 l buffer B in a 1.5 ml Eppendorf tube on ice,
followed by gently mixing and adding the buffer to the sample for 
imaging. NSTORM was performed using a Nikon Storm micro-
scope equipped with 405, 488, 561, and 633 nm lasers and propri-
etary software for image reconstruction.
Cross-linking to pacFACer and click chemistry-mediated 
tagging with fluorophores
Astrocytes were incubated under protection from light for 5–60 
min in DMEM medium with vehicle (1:1,000 ethanol/2% dodec-
ane) or 5 M of the bifunctional ceramide analog, pacFACer 
(Avanti Polar Lipids) diluted 1:1,000 from a stock in ethanol/2% 
dodecane. Cells were UV irradiated at 365 nm for 15 min at room 
temperature and fixed with 4% p-formaldehyde/0.5% glutaralde-
hyde/PBS for 15 min. Unbound pacFACer was removed by washing 
and fixing with ice-cold methanol for 15 min. For immunocyto-
chemistry, cells were washed with PBS, equilibrated with click re-
action buffer, and the click reaction performed using the Click-iT 
cell reaction buffer kit using Alexa Fluor 594-azide or TAMRA-
azide-biotin as fluorophores following the manufacturer’s proto-
col (Life Technologies).
pacFACer cross-linking and streptavidin pull-down
Homogenates of primary cultured astrocytes were incubated 
with pacFACer (10 M) for 30 min at room temperature. The 
homogenate was UV irradiated at 365 nm for 20 min. Unbound 
pacFACer was removed by chloroform/methanol precipitation. 
Protein precipitates were dissolved with 1% SDS in 50 mM Tris-
HCl buffer (pH 7.5) and sonicated. The click reaction was per-
formed using the Click-iT protein reaction buffer kit (Thermo 
Fisher Scientific) with 500 M of biotin azide (Sigma-Aldrich) 
following the manufacture’s protocol. Unbound biotin azide 
was removed by chloroform/methanol precipitation. The re-
sulting protein pellets were dissolved in 1% SDS in 50 mM 
Tris-HCl buffer (pH 7.5), diluted to 0.1% SDS for pull-down 
experiment. The insoluble materials were removed by centrifu-
gation at 20,000 g for 5 min at room temperature. Supernatants 
equivalent to the same amount of protein were incubated with 
25 l of preequilibrated NeutrAvidin beads (Thermo Fisher 
Scientific) for 2 h at room temperature. Beads were washed 
10 times with 0.1% SDS in 50 mM Tris-HCl buffer (pH 7.5). For 
immunobloting, pacFAcer-binding proteins were eluted with 
SDS-sample buffer containing 10% 2-mercaptoethanol for 
30 min at 60°C.
Affinity purification using ceramide beads
Ceramide-coated beads (P-BCer, Echelon Bioscience) and con-
trol beads (P-B000, Echelon Bioscience) were incubated with an 
equal amount of astrocyte lysates. In detail, primary cultured as-
trocytes were harvested in ceramide binding buffer [20 mM Tris-
HCl, 150 mM NaCl, and 1 mM EDTA (pH 7.5) supplemented 
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with protein inhibitor cocktail (Roche)]. The cells were homoge-
nized by glass homogenizer on ice, and complete lysis of cells was 
achieved by sonication. After insoluble debris was removed by 
centrifugation at 20,800 g for 30 min at 4°C, Triton X-100 was 
added to the supernatant at 0.25% of final concentration. A 20 l 
slurry of ceramide beads and control beads was added to the su-
pernatant and incubated at 4°C overnight under rotary agitation. 
Beads were harvested by centrifugation at 4°C, 500 g for 5 min and 
washed four times with ceramide binding buffer supplemented 
with 0.25% Triton X-100. The bound proteins were eluted by SDS-
sample buffer containing 10% 2-mercaptoethanol for 30 min at 
60°C and then subjected to SDS-PAGE either for immunoblotting 
or Coomassie staining. Stained bands were cut out and subjected 
to proteomics analysis.
pacFACer ELISA and cross-linking to recombinant tubulin
Binding assays were performed using pacFACer lipid ELISA 
as described previously (19, 20, 24). Briefly, pacFACer (500 ng 
in 100 l ethanol) was coated on 96-well Immulon-1B ELISA 
plates (Thermo Fisher Scientific/Life Technologies) and washed 
with PBS. Nonspecific binding sites were blocked by incuba-
tion for 1 h at 37°C with 100 l of 1% BSA in PBS. Tubulin 
purified from pig brain (80 ng/l, T240-T240-A; Cytoskele-
ton, Denver, CO) in PBS was incubated for 1 h at 37°C. Wells 
were UV irradiated at 365 nm for 15 min at room temperature. 
Unbound tubulin was removed by washing four times with PBS 
and then the click reaction performed using the Click-iT cell 
reaction buffer kit with Cy7.5-azide as fluorophore following 
the manufacturer’s protocol (Life Technologies). Click chem-
istry reagent was removed and the wells were washed four 
times with PBS. SDS sample buffer was added into the wells to 
collect protein samples.
Protein identification
Gel bands were excised from SDS-PAGE gels, cut into 1 mm 
pieces, destained using 50% acetonitrile (ACN) in 25 mM ammo-
nium bicarbonate, dried, reduced with dithiothreitol, alkylated us-
ing iodoacetamide, and digested overnight using trypsin. Peptides 
were extracted using 5% formic acid in 50% ACN and were dried. 
Peptide digests were analyzed on an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Fisher Scientific) coupled with an Ultimate 
3000 nano-UPLC system (Thermo Fisher Scientific). Two microli-
ters of reconstituted peptide were first trapped and washed on a 
Pepmap100 C18 trap (5 m, 0.3 × 5 mm) at 20 l/min using 2% 
ACN in water (with 0.1% formic acid) for 10 min and then separated 
on a Pepman 100 RSLC C18 column (2.0 m, 75 m × 150 mm) 
using a gradient of 2–40% ACN with 0.1% formic acid over 40 min 
at a flow rate of 300 nl/min and a column temperature of 40°C.
Samples were analyzed by data-dependent acquisition in posi-
tive mode using an Orbitrap MS analyzer for precursor scan at 
120,000 FWHM from m/z 300 to 1,500 and ion-trap MS analyzer 
for MS/MS scans at top speed mode (3 s cycle time). Collision-
induced dissociation was used as fragmentation method. Raw data 
were processed using Proteome Discoverer (v1.4; Thermo Fisher 
Scientific) and submitted for SequestHT search against the Uni-
Prot database pertinent to the origin of the sample. Fixed value 
PSM validator algorithm was used for peptide spectrum matching 
validation. SequestHT search parameters were 10 ppm precursor 
and 0.6 Da product ion tolerance, with static carbamidomethyl-
ation (+57.021 Da).
PLAs and quantitative analysis
Astrocytes were grown on glass coverslips. Cells were fixed with 
4% p-formaldehyde/0.5% glutaraldehyde/PBS for 15 min at 
37°C and then permeabilized by incubation with 0.2% Triton 
X-100 in PBS for 5 min at room temperature. Nonspecific binding 
sites were blocked with Duolink PLA blocking solution (Sigma-
Aldrich) for 1 h at 37°C. The primary antibodies used were: anti-
ceramide rabbit IgG (1:100, our laboratory) (20, 24), anti-VDAC1, 
and anti-tubb 4/5. Secondary PLA probes, anti-rabbit PLUS affinity-
purified donkey anti-rabbit IgG (H+L), anti-goat MINUS affinity-
purified donkey anti-goat IgG (H+L), and anti-mouse MINUS
affinity-purified donkey anti-mouse IgG (H+L), were diluted 1:5
in 1× antibody diluent buffer and samples incubated for 1 h at
37°C. After washing, ligation and amplification steps were per-
formed following the manufacturer’s protocol (Sigma-Aldrich).
Coverslips were mounted using Fluoroshield supplemented with
DAPI (Sigma-Aldrich) to visualize the nuclei. Zeiss LSM780 up-
right confocal microscopy was performed as described in one of
the previous sections. Zen software was used for initial image ac-
quisition and dots counted using ImageJ. Images obtained with
secondary antibody only were used as negative controls represent-
ing the background intensity in a particular laser channel.
Isolation of mitochondria and coimmunoprecipitation assay
HEK293T cells were seeded on the 100 mm dishes with 35–
40% of density, in the absence or presence of 3 M FB1 (116355-
83-0; Cayman, Ann Arbor, MI). Sixty hours later, the untreated
cells and the treated cells were harvested and washed twice with
ice-cold PBS. The cell pellets were transferred into a Dounce ho-
mogenizer and lysed with 2 ml of ice-cold mitochondria extrac-
tion buffer [125 mM sucrose, 250 mM mannitol, 10 mM HEPES,
10 mM EGTA, 0.01% BSA, and protease inhibitors (pH 7.2)]. To
enrich for mitochondria, the homogenate was transferred into a
centrifuge tube and cell debris pelleted at 700 g, 4°C for 10 min.
The supernatant was centrifuged once again under the same
conditions and subsequently, transferred to a new ice-cold tube
followed by centrifugation at 10,000 g for 15 min at 4°C. The mi-
tochondrial pellet was resuspended in 1 ml of lipid binding buffer 
[20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 7.5), and 1%
digitonin, supplemented with protein inhibitor cocktail (Roche)] 
and complete lysis of mitochondrial membranes was achieved by
sonication. Insoluble debris was removed by centrifugation at
10,000 g for 15 min at 4°C. The protein concentration in the su-
pernatants from untreated cells and treated cells was adjusted to
the same concentration and the same volume. Lysates were pre-
cleared with Pierce protein A/G magnetic beads (88802; Pierce
Biotechnology, Rockford, IL) and then incubated overnight with
nonspecific mouse IgG (control) or anti -tubulin mouse IgG at
4°C under rotational movement. The next morning, 15 l of
Pierce protein A/G magnetic beads were added to the samples
and incubated for 2 h at room temperature under rotational
movement. The beads were harvested and washed three times by
lipid binding buffer without digitonin. Protein bound to the
beads was eluted by SDS-sample buffer containing 10% 2-mercap-
toethanol for 30 min at room temperature. The protein prepa-
ration was subjected to SDS-PAGE for immunoblotting using
anti-VDAC1 rabbit IgG.
ATP determination
Wild-type and fro/fro astrocytes (106 cells) were detached using 
trypsin/EDTA solution and resuspended in ice-cold PBS. Total 
cellular ATP was determined following the fluorescence protocol 
as described in the manual provided by the supplier (Abcam). All 
measurements were performed in triplicate and normalized to 
cell number and protein.
Morphometric analysis of mitochondria
Measurement of mitochondrial length (L) and width (W), pe-
rimeter (P), and area (A) was achieved using ImageJ after correction 
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for contrast and background. Mitochondrial morphology was an-
alyzed using standard protocols for quantitation of mitochondrial 
length (L), aspect ratio (L/W), and form factor (P2/4A), as pre-
viously described (64).
Statistical analysis
The mean, SEM, and statistical tests of control and treatment 
samples were calculated using GraphPad Prism. Student’s t-test 
was used to compare two groups, one-way ANOVA with Bonfer-
roni post hoc test for three or more groups. Values of at least P < 
0.05 were considered significant.
Miscellaneous
For immunoblot analysis, protein concentrations were deter-
mined using the RC/DC protein assay, in accordance with the 
manufacturer’s (Bio-Rad) instructions. Equal amounts of protein 
were loaded onto a 4–20% gradient gel, and SDS-PAGE was 
performed using the Laemmli method. For immunoblotting, 
membranes were first blocked with 5% dry milk in PBST (PBS 
containing 0.1% Tween-20) and incubated with primary antibod-
ies in the blocking buffer overnight at 4°C. Membranes were 
then washed three times with PBS/0.05% Tween and incubated 
with the appropriate horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h at room temperature. After washing, 
bands were detected using an Odyssey imaging system from 
Licor or Pico and Femto ECL assay from Pierce/Thermo Fisher 
Scientific.
RESULTS
Mitochondria in ceramide-depleted astrocytes are 
resistant to A-induced fragmentation and show  
increased motility
Our previous studies showed that incubation with A42 
leads to increased levels of ceramide in primary cultured 
astrocytes and that nSMase2 deficiency reduces ceramide 
levels and sensitivity of astrocytes to A-induced apoptosis 
(supplemental Fig. S1A) (4). In addition, it has been shown 
that A42 induces fragmentation of mitochondria (44). 
Therefore, we tested to determine whether mitochondria 
in nSMase2-deficient astrocytes were resistant to A-induced 
fragmentation. Figure 1A shows that overnight exposure to 
1 M A42 led to fragmented mitochondria in wild-type, 
but not in nSMase2-deficient, astrocytes (see supplemental 
Fig. S1B, C for controls). Fragmentation led to about 50% 
reduction in mitochondrial length, aspect ratio, and form 
factor (Fig. 1B–D), consistent with previous studies show-
ing similar effects of amyloid on mitochondrial morphol-
ogy (64). As an alternative approach to deplete cells of 
ceramide, we used the CerS inhibitor, FB1, which also pro-
tected astrocytes from mitochondrial fragmentation (sup-
plemental Fig. S1A, ceramide profile; supplemental Fig. 
S1D, E, mitochondria). These results suggested that in-
dependent of the affected metabolic pathway (via nSMase2 
or CerS-mediated de novo biosynthesis), ceramide deple-
tion was protective for mitochondria in astrocytes.
When evaluating time-lapse images of mitochondria la-
beled with MitoTracker or CytoPaint, we noticed that nu-
merous mitochondria in nSMase2-deficient or FB1-treated 
astrocytes were rapidly moving, while those in wild-type 
cells were predominantly resting (supplemental Movies, 
supplemental Fig. S2A–C). Increase of mitochondrial mo-
tility by ceramide depletion was unexpected and has not 
been described before. Motility was quantified by deter-
mining colocalization of individual mitochondria in con-
secutive time frames of time-lapse images and comparing 
wild-type with nSMase2-deficient astrocytes. Mitochondria 
at the cell periphery of nSMase2-deficient astrocytes showed 
about 30% higher motility than those in wild-type cells, 
while mitochondria close to the nucleus were almost im-
motile (Fig. 1E, F). These results indicated an unknown 
function of ceramide in the regulation of mitochondrial 
distribution or motility.
Ceramide is enriched in mitochondrial-associated 
membranes and codistributes with microtubules and 
tubulin
To begin testing the role of ceramide in mitochondria, 
we visualized the distribution of ceramide within cellular 
compartments important for mitochondrial motility using 
a rabbit polyclonal anti-ceramide antibody originally de-
veloped in our laboratory (24). Figure 2A, B shows that the 
ceramide label codistributed with sigma 1 receptor (Sig-
maR1), a marker for MAMs, and MitoTracker, a marker 
for mitochondria. In nSMase2-deficient or FB1-treated 
wild-type cells, codistribution of ceramide label with MAMs 
and mitochondria was significantly reduced (Fig. 2B; sup-
plemental Fig. S2D, E), indicating that ceramide gener-
ated by both nSMase2 and CerS is critical for ceramide 
enrichment in a subpopulation of MAMs, particularly in 
the cell periphery (arrows in Fig. 2B). We refer to this 
compartment as ceramide-enriched MAMs or CEMAMs.
Because peripheral mitochondria in ceramide-depleted 
cells showed higher motility, we tested to determine whether 
ceramide depletion would alter the distribution of CEMAMs 
along microtubules. Figure 2C shows that codistribution 
of the ceramide label with acetylated tubulin was signifi-
cantly reduced in nSMase2-deficient astrocytes. The mor-
phological appearance of ceramide-labeled vesicular and 
tubular structures along microtubules (arrows in Fig. 2C, 
left panel) in wild-type cells prompted us to analyze the 
codistribution of ceramide with microtubules at higher 
resolution. Figure 3A, B shows that ceramide was colabeled 
with microtubules and appeared to form contact structures 
that were also detected by super-resolution fluorescence 
microscopy (NSTORM, arrows in Fig. 3B, C). Codistribu-
tion of ceramide with acetylated tubulin was also detected 
in astrocytes in tissue sections of mouse brain, confirming 
the results obtained with cell cultures (supplemental Fig. 
S3A). The results obtained with anti-ceramide rabbit IgG 
were confirmed using anti-ceramide mouse IgM, another 
antibody reported to detect ceramide using immunocyto-
chemistry (supplemental Fig. S3B) (24, 65). Despite partial 
overlap, the distribution of ceramide and acetylated tubu-
lin was not identical, consistent with the assumption that 
ceramide is primarily enriched in CEMAMs associated 
with microtubules as well as mitochondria. Figure 3D shows 
that ceramide was codistributed with mitochondria and 
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-tubulin, suggesting that potential interaction of ceramide 
with tubulin is important for the regulation of mitochon-
drial function and motility.
Tubulin is cross-linked to pacFACer and binds to ceramide
Our earlier studies showed that tubulin was coimmuno-
precipitated when pulling down intracellular vesicles using 
the anti-ceramide antibody (20). However, whether tubu-
lin interacts directly with ceramide and what the function 
of this potential interaction is remained unclear. To test 
this, we used a bifunctional ceramide analog (pacFACer) 
that can be UV-cross-linked to ceramide binding proteins 
and then derivatized by click chemistry with fluorophores 
or biotin, a novel labeling technique recently developed 
Fig. 1. Ceramide depletion increases resistance to A and mitochondrial motility. A: Wild-type and nSMase2-deficient astrocytes were incu-
bated overnight with 1 M A1-42 and mitochondrial morphology recorded after labeling with MitoTracker (pseudocolored in red). Panels on 
right side show details of panels on left side. Scale bars = 20 m (left) and 2 m (right). B–D: Morphometric analysis of mitochondria from 
wild-type and nSMase2-deficient astrocytes with (A) or without [control (Con)] A treatment. Mitochondrial length [**P < 0.01 (B)], aspect 
ratio [**P < 0.01 (C)], and form factor [***P < 0.001 (D)] were calculated using ImageJ (n = 3 independent cell cultures with five randomly 
selected areas per culture). E, F: Mitochondrial motility. Fifteen frames (one frame per minute) of wild-type and nSMase2-deficient astrocytes 
were recorded using time-lapse in vivo imaging. Mitochondria were labeled with CytoPainter (t0 pseudocolored in green, t1 pseudocolored in 
red). Motility of perinuclear (N) and peripheral (P) mitochondria was quantified using colocalization analysis (ImageJ) in two consecutive 
time frames (t0 and t1) (n = 3 independent cell cultures with five randomly selected areas per culture; **P < 0.01; scale bar = 50 m).
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Fig. 2. Ceramide is colocalized with MAMs, peripheral mitochondria, and microtubules, which is prevented by nSMase2 deficiency and 
FB1 treatment. A: Immunocytochemistry using MitoTracker (pseudocolored in blue) and antibodies against ceramide (rabbit IgG, pseudo-
colored in red) and SigmaR1 (goat IgG, pseudocolored in green). The left panel shows the overview with the inset frame at higher resolution 
shown in the right panel. The middle panel shows the profile of fluorescence signal intensity along the dashed line in the right panel, indicat-
ing colabeling of ceramide and SigmaR1 at mitochondria (white color in image). The y-axis in the middle panel shows arbitrary units of fluo-
rescence signal intensity. B: Colocalization of ceramide (pseudocolored in red) with MitoTracker (pseudocolored in green) in WT and 
nSMase2-deficient astrocytes. The arrows point at peripheral mitochondria (n = 5 independent cultures; **P < 0.01). C: Colocalization of 
ceramide (pseudocolored in red) and acetylated tubulin (pseudocolored in blue) in WT and nSMase2-deficient astrocytes. Mitochondria are 
pseudocolored in green (n = 4 independent cultures; ***P < 0.001).
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for sphingolipids (19, 66–68). In addition, we used ceramide-
linked agarose beads to pull down and identify ceramide 
binding proteins from cell lysates.
In a cell-free assay, lipid-adsorptive ELISA plates were 
coated with pacFACer and then incubated with purified tu-
bulin from pig brain. After UV cross-linking, unbound tu-
bulin was washed out and the cross-linked protein tagged 
with Cy7.5 and then eluted with SDS sample buffer. Figure 
4A, B shows that only tubulin exposed to UV was labeled 
(lanes 7 and 9, arrow), while the control (without UV) re-
mained unlabeled (lanes 6 and 8). BSA was not signifi-
cantly cross-linked to pacFACer (Fig. 4A, B, lanes 4 and 9), 
although its concentration was more than 10-fold of that of 
tubulin (1 mg/ml vs. 0.08 mg/ml). A proteomics analysis 
of Cy7.5-labeled tubulin (Fig. 4A, B, lanes 7 and 9) led to 
the identification of the tryptic peptide, M363AATFIGN-
STAIQELFK379, in the -tubulin isoform tubb4a (UniProt 
accession number F2Z5K5) as the candidate sequence 
cross-linked to pacFACer.
A preliminary modeling analysis of potential ceramide 
binding sites using the UCSF Zinc database (C16:0 ce-
ramide, zinc_40164304.mol2), RCSB PDB database ( 
tubulin dimer, ijff.pdb), and Swissdocks program sug-
gested three potential ceramide binding sites in the dimer 
(supplemental Fig. S3C) with binding energies of more 
than 8 kcal/mol (equivalent to an equilibrium constant 
of <1 M). As a comparison, the intracellular tubulin 
concentration can go up to about 1 mg/ml or 20 M, 
which is slightly above the threshold for microtubule self-
assembly (0.8 mg/ml) (69, 70). Site 1 was close to the may-
tansine and GTP binding sites in the vicinity of helices 
H3-H3′ (71). Site 2 was similar to the taxol binding site 
close to the M-loop region (72). Site 3 was in proximity to 
the C-terminal helices H10-H11 and overlapped with the 
peptide identified by proteomics analysis (supplemental 
Fig. S3C, D). The molecular modeling analysis was consis-
tent with the results from pacFACer cross-linking and may 
therefore represent potential binding sites for ceramide in 
- and -tubulin.
To confirm cross-linking to cellular tubulin, homoge-
nized astrocytes were incubated with pacFACer and the 
cross-linked protein tagged with biotin followed by strepta-
vidin pull-down. Proteomics analysis and immunoblotting sug-
gested that -tubulin (UniProt accession number P99024) 
was pulled down from the cross-linked sample (Fig. 4C, 
lane 3). Tubulin was not significantly cross-linked to other 
photoactivatable lipids, including photoactivatable fatty 
acid and sphingosine, demonstrating specificity of the re-
action with pacFACer (67, 68, 73). In addition, we used 
ceramide-linked agarose beads to test which tubulin iso-
forms from a cellular homogenate bind to ceramide (Fig. 
4D, lane 2). Proteomics analysis of the eluate showed that 
various -tubulin (P68369, P05213, P68373, and Q9JJZ2) 
and -tubulin (P99024, P68372, Q7TMM9, Q9ERD7, and 
Fig. 3. Ceramide forms contact structures with mi-
crotubules and codistributes with tubulin. A: Confocal 
immunofluorescence microscopy using anti-ceramide 
rabbit IgG (pseudocolored in red) and anti-acetylated 
tubulin mouse IgG (pseudocolored in green). The im-
age shows Z-scan projection onto one plane. Scale bar = 
20 m. B: The image shows detail from A (frame) at 
higher magnification. Scale bar = 2 m. C: NSTORM 
using antibodies as described in A. Arrows point at po-
tential contact structures (yellow) between ceramide 
(CEMAM) and microtubules. Scale bar = 500 nm. D: 
Confocal immunofluorescence microscopy using as-
trocytes labeled with MitoTracker (pseudocolored in 
blue) and then subjected to immunocytochemistry 
with anti--tubulin mouse IgG (pseudocolored in red) 
and anti-ceramide rabbit IgG (pseudocolored in green). 
The right panel shows fluorescence signal intensity 
and distribution indicating colocalization of antigens 
at mitochondria.
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Fig. 4. Cross-linking of pacFACer to tubulin and binding to ceramide. A, B: Tubulin from pig brain was cross-linked to pacFACer, tagged 
with Cy7.5 azide, and then separated by SDS-gel electrophoresis [fluorescence scanning (A); Coomassie staining (B)]. Lane 1, control tubu-
lin (1 g); lane 2, protein standard; lane 3, BSA  UV; lane 4, BSA + UV; lane 5, protein standard; 6, tubulin  UV; lane 7, tubulin + UV; 
lane 8, tubulin + BSA  UV; lane 9, tubulin + BSA + UV. The arrow points at the tubulin band. C: Protein from astrocytes was cross-linked to 
pacFACer, tagged with biotin azide, and the protein pulled down with streptavidin agarose beads. Immunoblot was performed using 
-tubulin mouse IgG Lane 1, click reaction without pacFACer; lane 2, with pacFACer  UV; lane 3, with pacFACer + UV. D: Pull-down of 
protein with control agarose (Con) or ceramide-linked agarose beads (Cer). The immunoblot of protein in the eluate was probed with 
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Q922F4) isoforms were among the ceramide-binding pro-
teins. Immunocytochemistry at higher resolution showed 
that ceramide colabeled with contact structures between 
microtubules and mitochondria (Fig. 4E, arrows), sug-
gesting that ceramide is important for the function of 
membranous contact sites between microtubules and 
mitochondria.
pacFACer-cross-linked tubulin is translocated from 
the perinuclear region to peripheral CEMAMs and 
codistributes with ceramide
Based on the observation that pacFACer was cross-linked 
to tubulin, we investigated to determine whether intracel-
lular pacFACer label colocalized with ceramide and tubu-
lin at CEMAMs, mitochondria, or microtubules. Initially, 
we immediately fixed astrocytes after pacFACer incubation 
and UV cross-linking (0 h post-cross-linking), a procedure 
described for other bifunctional sphingolipid analogs with 
only minimal metabolic turnover of ceramide into other 
sphingolipid derivatives that may cross-link to proteins 
(68). In contrast to these previous studies, we also intro-
duced a post-cross-linking incubation step (24 h), allowing 
intracellular trafficking of the pacFACer-linked protein. 
pacFACer remaining in the cell, but not cross-linked and 
further metabolized to other sphingolipid analogs (e.g., 
sphingomyelin), was washed out with methanol following 
fixation. The pacFACer-linked protein was visualized using 
click chemistry-mediated tagging with fluorophores.
Fixation immediately after cross-linking (0 h post-cross-
linking) led to pacFACer labeling of a perinuclear com-
partment (Fig. 5A) that partially colocalized with calnexin, 
a chaperone and calcium regulator found in the ER and 
some ER-derived subcompartments, such as MAMs (Fig. 
5C) (74). There was little or no distribution of pacFACer to 
the cell periphery (area labeled P in Fig. 5C). The pac-
FACer-labeled compartment also partially colocalized with 
GM130 (supplemental Fig. S3E), a golgin family protein 
important for microtubule assembly and ER-to-Golgi traf-
ficking (75), suggesting that initial cross-linking of pacFACer 
to protein was limited to the perinuclear ER and/or Golgi. 
Incubation for 24 h post-cross-linking led to the gradual 
appearance of pacFACer labeling in the cell periphery 
(Fig. 5B, D). Figure 5E shows imaging results obtained af-
ter ectopic expression of the GFP-tagged ER marker pro-
tein, Sec61 (Sec61-GFP), in HEK293T cells. Codistribution 
of the pacFACer label with Sec61-GFP (solid arrows) and 
MitoTracker (dashed arrows) was consistent with the re-
sults obtained with pacFACer cross-linking in astrocytes.
Next, we tested to determine whether pacFACer and ce-
ramide were codistributed in the same compartment(s), 
particularly microtubules, MAMs, and mitochondria. Fig-
ure 6A–C shows that pacFACer and ceramide were colabeled 
with isoforms of tubulin along microtubules. Colabeling 
was also detected in MAMs (arrows in Fig. 6D), suggesting 
that pacFACer-cross-linked protein was transported to 
CEMAMs to contact structures with microtubules and mi-
tochondria. Figure 7A–E shows that pacFACer and ce-
ramide were codistributed at peripheral mitochondria 
(arrows in Fig. 7A) along microtubules (arrows in Fig. 7B). 
Using higher resolution confocal microscopy (Fig. 7C) and 
STORM (Fig. 7D), we found that codistribution of pacFACer 
with ceramide was limited to contact structures (arrows in 
Fig. 7D, right panel), consistent with the assumption that 
pacFACer-cross-linked tubulin was localized in CECs, par-
ticularly CEMAMs that formed attachment sites with micro-
tubules and mitochondria, as shown in Fig. 4E (arrows).
Similar to the effect of ceramide depletion on the dis-
tribution of CEMAMs (Fig. 2B), we tested to determine 
whether nSMase2 deficiency reduced colabeling of pac-
FACer with mitochondria. While nSMase2 deficiency did 
not significantly change codistribution of pacFACer with 
mitochondria located closer to the nucleus (area of inter-
est labeled N), there was a significant reduction of label at 
peripheral mitochondria (area of interest labeled P) in 
nSMase2-deficient astrocytes (Fig. 7E, F). Taken together, 
these results suggested that after initial cross-linking in the 
perinuclear ER (or Golgi), pacFACer-cross-linked tubulin 
was distributed to CEMAMs and mitochondria, which was 
prevented by ceramide depletion.
Ceramide depletion reduces association of ceramide with 
tubulin at mitochondria
Our results were consistent with the assumption that 
tubulin was cross-linked to pacFACer and transported to 
CEMAMs. Therefore, we tested to determine whether ce-
ramide was associated with tubulin at CEMAMs, and 
whether CAT formation or distribution was reduced by 
ceramide depletion in nSMase2-deficient or FB1-treated 
astrocytes. Apart from cross-linking of pacFACer, there is 
currently no assay able to visualize direct binding of ce-
ramide to a particular protein in intact cells. Recently, 
PLAs have been developed to detect formation of protein 
or other complexes by immunocytochemistry. PLAs use 
short cDNA strands attached to secondary antibodies to 
amplify a fluorescence signal by rolling circle PCR if the 
primary antibodies are in close vicinity (<40 nm), indicating 
complex formation of the antigens (76, 77). To date, the 
anti-ceramide IgG is the only ceramide-specific antibody 
that can be used for PLA with commercially available sec-
ondary antibodies.
Figure 8A–D shows that PLA signals using anti-ceramide 
[rabbit IgG (+) strand secondary antibody] and anti--
tubulin [mouse IgG () strand secondary antibody] were 
predominantly associated with cross-linked pacFACer and 
MitoTracker labeling, suggesting that CAT complexes are 
formed at contact structures of CEMAMs with mitochon-
dria. Pairing nonspecific rabbit IgG or mouse IgG with 
anti-rabbit IgG (+) and anti-mouse IgG () did not yield 
anti-detyrosinated -tubulin rabbit IgG. E: High-resolution confocal microscopy showing arrangement of microtubules (MT), mitochondria 
(Mito), and ceramide (middle and right panels show z-stack reconstruction along dashed line in the left panel). The arrows point at contact 
structures of ceramide (CEMAM) with microtubules and mitochondria.
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PLA signals demonstrating specificity of the method (not 
shown). It should be noted that at higher resolution, the 
dot-like PLA signal did not exactly codistribute with the an-
tigens or site of antibody binding, but rather showed a 
stalk-drop appearance (arrows in Fig. 8D) as the signal for 
ceramide-tubulin interaction colocalized with pacFACer-
labeled mitochondria (dashed arrows point at the initial 
binding sites for the secondary antibodies). The number of 
PLA signals was reduced in nSMase2-deficient astrocytes 
and cells (astrocytes and HEK293T) treated with the CerS 
inhibitor, FB1 (Fig. 8B, E, left panel, only HEK293T cells 
are shown), consistent with decreased colocalization of ce-
ramide and pacFACer at mitochondria. Figure 8F confirms 
colocalization of the PLA signal for the CAT complex with 
mitochondria (arrows).
Ceramide depletion reduces complex formation between 
tubulin and VDAC1 and increases cellular ATP levels
The formation of CAT complexes and its reduction by 
ceramide depletion implies that association with ce-
ramide may regulate the function of tubulin at mitochondria. 
Previous studies showing that tubulin closes VDAC1 sug-
gested that CAT may regulate VDAC1 (52, 54, 78). We 
performed PLAs for CAT-dependent formation of VDAC1-
tubulin complexes using anti-VDAC1 [rabbit IgG (+)] and 
anti-- or --tubulin [mouse IgG ()] antibodies with wild-
type and nSMase2-deficient astrocytes. Figure 9A, B and 
supplemental Fig. S4A, B show that nSMase2 deficiency 
or FB1-mediated inhibition of CerSs led to 70% reduction 
of the number of PLA signals for complex formation be-
tween VDAC1 and tubulin. Image analysis at higher resolu-
tion confirmed that the signals indicating VDAC1-tubulin 
complexes were located at mitochondria (Fig. 9C, D, sup-
plemental Fig. S4C), consistent with the localization of 
CATs (Fig. 8D, F).
To confirm the validity of the PLA results, we performed 
coimmunoprecipitation assays using anti--tubulin mouse 
IgG for the immunoprecipitation and anti-VDAC1 rabbit 
IgG for the immunoblotting reaction with HEK293T cells 
with or without FB1 treatment. Figure 9E, F shows that in 
HEK293T cells, the number of PLA signals for the VDAC1-
tubulin complex was reduced by ceramide depletion to the 
Fig. 5. Protein cross-linked to pacFACer is trans-
ported from the perinuclear region to the cell periph-
ery. A, B: Primary cultured astrocytes were incubated 
with pacFACer and either immediately fixed after 
cross-linking (A) or incubated for another 24 h prior 
to fixation (B) and subjected to click chemistry-medi-
ated labeling with Alexa647-azide (pseudocolored 
in red) and immunocytochemistry using an antibody 
against acetylated tubulin (mouse IgGs, pseudocol-
ored in green). C, D: Experiment performed as in A 
and B, and immunolabeled for calnexin (mouse IgG, 
pseudocolored in green). N, perinuclear region; P, 
cell periphery. Scale bars = 10 m. E: HEK293T cells 
expressing the ER marker, Sec61-GFP (Secgfp) (pseu-
docolored in green), cross-linked with pacFACer (pac) 
(pseudocolored in red, solid arrows), and labeled with 
MitoTracker (Mito) (pseudocolored in blue, dashed 
arrows). The left panel is an overview with framed area 
shown at high resolution in the middle and right pan-
els. Scale bars = 20 (left panel) and 2 m (middle and 
right panels).
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same extent as with astrocytes (supplemental Fig. S4A, B). 
For the coimmunoprecipitation experiment, digitonin 
(1%) was used as a detergent because it is known to pre-
serve the membrane environment in ceramide biosynthesis 
and it is commonly used for solubilization of proteins from 
the OMM (79–81). Figure 9G shows that ceramide de-
pletion reduced the amount of coimmunoprecipitated 
VDAC1 (nontreated cells and nonspecific mouse IgG were 
used as controls) consistent with the decrease of the num-
ber of PLA signals for the VDAC1-tubulin complex in 
HEK293 cells (Fig. 9E, F). The reverse immunoprecipita-
tion reaction using anti-VDAC1 rabbit IgG and anti--
tubulin for immunoblotting did not show a signal, possibly 
due to inaccessibility of VDAC1 to its antibody in digitonin-
solubilized membranes (not shown).
While tubulin-mediated closure of the VDAC1 channel 
was shown to block ADP/ATP transport, the effect of this 
regulation on the intracellular ATP concentration has not 
been reported yet. There are numerous reports, however, 
that VDAC1 downregulation profoundly decreases levels of 
intra- and extracellular (secreted) ATP (45, 46, 82). Based 
on our observation that ceramide depletion decreases 
complex formation between tubulin and VDAC1, we tested 
to determine whether reducing ceramide would upregu-
late cellular ATP levels. Figure 9H, I shows that ATP levels 
of nSMase2-deficient or FB1-treated astrocytes were 40% 
higher than those in wild-type controls. Increase of cellular 
ATP by ceramide depletion was consistent with higher mi-
tochondrial motility and resistance to A, although further 
research is needed to understand these potentially related 
effects. Notwithstanding this limitation, our research strongly 
suggests that there is a novel function of ceramide for mito-
chondria regulating ATP levels, motility, and resistance to 
A mitotoxicity.
DISCUSSION
For two decades, research on ceramide in mitochondria 
was focused on its role in the induction of apoptosis. This 
focus appeared justified because strong experimental 
evidence supported the notion that ceramide generated by 
SMase(s) at mitochondria induced apoptosis, probably by 
forming channels for pro-apoptotic proteins in the OMM 
(59, 61, 83–85). However, the abundance of ceramide in 
MAMs under physiological conditions also suggested other 
functions of ceramide that were only poorly understood. 
Compartmentalization of ceramide in microdomains (rafts) 
or more extended membrane areas and its physiological 
function remained elusive. About 10 years ago, our labora-
tory developed a polyclonal ceramide antibody that proved 
Fig. 6. Protein cross-linked to pacFACer colocalizes 
with ceramide at microtubules and CEMAMs in the 
cell periphery. A–C: Confocal immunofluorescence 
microscopy (Z-scan projections) using primary astro-
cytes subjected to pacFACer cross-linking and tagging 
with Alexa647 azide (24 h post-cross-linking, pseu-
docolored in blue) and antibodies against ceramide 
(rabbit IgG, pseudocolored in green) and acetylated 
tubulin [mouse IgG (A)], -tubulin [mouse IgG (B)], 
-tubulin [mouse IgG (C)], or -tubulin tubb4/5 
[mouse IgG (D)] all pseudocolored in red. Scale bars = 
2 m. D: Same as in A–C, but using antibody against 
SigmaR1 (goat IgG, pseudocolored in red). The ar-
rows point at pacFACer-labeled CEMAMs.
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Fig. 7. Protein cross-linked to pacFACer colocalizes with ceramide at mitochondria in cell periphery, which is prevented in nSMase2-deficient 
cells. A: Astrocytes subjected to pacFACer cross-linking and labeled with MitoTracker (24 h post-cross-linking, pseudodcolored in blue) 
underwent click chemistry-mediated tagging with Alexa647 azide (pseudocolored in red) and immunocytochemistry using anti-ceramide 
rabbit IgG (pseudocolored in green). The left panel shows an overview with panels on the right showing details of the framed area at high 
resolution. The arrow in the left panel points at the perinuclear region with codistribution of pacFACer and ceramide. The arrows in 
the panels on the right point at peripheral mitochondria colabeled for ceramide and pacFACer. B: pacFACer/Alexa647-tagged protein 
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useful for visualizing ceramide in fixed cells and tissues us-
ing immunocytochemistry (24). It was shared with many 
other laboratories to determine the intracellular distribu-
tion of ceramide and was instrumental to our research on 
CECs (18–21, 25, 27). Most recently, this antibody allowed 
the visualization of ceramide rafts using super-resolution 
microscopy (dSTORM) (18), clearly demonstrating that 
the distribution of ceramide in cellular membranes is 
anisotropic and regulated by SMase(s).
In addition to anti-ceramide IgG, a new generation of 
ceramide analogs was developed to use click chemistry-me-
diated addition of fluorophores after the analog inserted 
into cellular membranes (66, 86). We and our collabora-
tors showed that these analogs are codistributed with CECs 
detected by the antibody (25). Using a modified version of 
these analogs, bifunctional ceramide analogs (pacFACer) 
that can be UV-cross-linked to ceramide binding proteins 
and derivatized using click chemistry, we demonstrated 
that pacFACer can be cross-linked to protein in CECs (19). 
In the present study, we discovered that CEMAMs contain 
protein cross-linked to pacFACer. While it is currently not 
possible to clearly identify the cross-linked protein by im-
munocytochemistry, pull-down assays and PLAs suggest 
that tubulin is a protein bound by ceramide in CEMAMs. 
This assumption is supported by the observation that 
ceramide depletion by nSMase2 deficiency or CerS inhibi-
tion with FB1 reduces the number of PLA signals at mito-
chondria when using anti-ceramide and tubulin antibodies. 
(pseudocolored in red) is colocalized with peripheral mitochondria (Tom 20, pseudocolored in green) along microtubules (acetylated tu-
bulin, pseudocolored in blue). C, D: Confocal immunofluorescence microscopy [Z-scan projection onto one plane (C)] and NSTORM su-
per resolution fluorescence microscopy of pacFACer-cross-linked protein tagged with Alexa647 azide [pseudocolored in green (D)] 
combined with anti-Tom 20 rabbit IgG (Atto488, pseudocolored in green). The panel on the left side in D shows an overview of the NSTORM 
image; the panels on the right show details of the frame in the left panel. The arrows indicate colocalization at potential contact sites between 
ceramide (CEMAMs) and mitochondria. Scale bar = 500 nm. E, F: Colocalization of pacFACer (pseudocolored in red) and MitoTracker 
(pseudocolored in green) in WT and nSMase2-deficient astrocytes. The frames in the figure panels indicate perinuclear (N) and peripheral 
(P) mitochondria, respectively (scale bar = 5 m; n = 5 independent cell cultures with five randomly selected areas per culture; **P < 0.01).
Fig. 8. Ceramide depletion reduces formation of 
CAT complexes at mitochondria. A–D: PLAs indicat-
ing complex formation between ceramide and tubu-
lin in astrocytes. Astrocytes subjected to pacFACer 
cross-linking and labeled with MitoTracker (24 h 
post-cross-linking, pseudocolored in red) underwent 
click chemistry-mediated tagging with Alexa647 
azide (pseudocolored in blue) and PLAs using anti-
ceramide rabbit IgG (+) and anti -tubulin mouse IgG 
() (PLA pseudocolored in green) in WT and nS-
Mase2-deficient astrocytes. Images are shown at higher 
magnification and association of PLA signals with pac-
FACer-labeled mitochondria (C, D). Stalk-drop ap-
pearance (solid arrow) of high resolution PLA signal 
attached to mitochondrium (dashed arrow, initial at-
tachment site of secondary antibodies) (D). E, F: PLA 
using HEK293T cells, anti-ceramide rabbit IgG (+), 
and anti--tubulin mouse IgG (). Signals for CAT 
complexes are pseudocolored in green; MitoTracker is 
pseudocolored in red. Scale bars = 20 m. F: Detail 
with arrows pointing at PLA signal at mitochondria 
(Z-scan in bottom panel). Scale bar = 2 m.
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Fig. 9. Ceramide depletion reduces VDAC1-tubulin complex formation at mitochondria and increases intracellular ATP levels. A–D: As-
trocytes were labeled with MitoTracker (pseuodcolored in red) and PLAs performed using anti-VDAC1 rabbit IgG (+) and anti--tubulin 
mouse IgG () (PLA pseudocolored in green). B: Quantitation of VDAC1-tubulin complexes in WT and nSMase2-deficient astrocytes 
(n = 4 independent cell cultures; **P < 0.01). C: Detail from A (frame in left panel) and fluorescence signal intensity profile indicating as-
sociation of PLA signals with mitochondria. D: Detail from C (frame). E, F: PLA using anti-VDAC1 rabbit IgG (+) and anti--tubulin mouse 
IgG () with nontreated and FB1-treated HEK293T cells. Signals for VDAC1-tubulin complexes are pseudocolored in green, MitoTracker is 
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It should be noted, however, that any PLA signal is evi-
dence for, but not absolute proof of, a complex because its 
components can still be about 40 nm apart.
Despite this caveat, there is solid evidence from inde-
pendent studies that ceramide binds directly to tubulin 
(20, 28, 29). Molecular modeling predicts that the affinity 
of tubulin for ceramide is relatively low (0.5–1 M), which 
may turn CAT into a sensor for free tubulin at physiologi-
cal levels in the cytosol to block VDAC1 and ATP release, 
provided that sufficient ceramide for CAT formation is 
available (Fig. 10A). On the other hand, if ceramide levels 
are low, formation of CAT is also reduced and ATP release 
and mitochondrial motility increased (Fig. 10B). Our 
model predicts that CEMAMs engage CAT into blocking 
VDAC1 in a zipper or Velcro-like way (Fig. 10C): simulta-
neous CAT formation in several complexes with VDAC1 
will stabilize the contact of CEMAMs to the OMM despite 
presumably lower affinity for the individual ceramide-tu-
bulin interaction. This interaction is likely to be mediated 
by a tubulin dimer with -tubulin binding to ceramide and 
the C-terminal tail of (detyrosinated) -tubulin reaching 
into the VDAC1 channel (Fig. 10D).
Previous studies using a similar or the same ATP assay as 
applied in our study showed that VDAC1 downregulation 
leads to reduced levels of intracellular ATP (45, 46, 82). This 
observation is quite remarkable because this assay does not 
distinguish between mitochondrial or cytosolic ATP levels, 
indicating that blocking VDAC1 will reduce both ATP pools. 
It should be noted, however, that the results of the ATP assay 
do not exclude the effect of ceramide on other ATP regula-
tory mechanisms, such as aerobic glycolysis or the activity of 
the adenine (ADP/ATP) nucleotide translocator (ANT), an 
ADP/ATP exchanger located in the inner mitochondrial 
membrane (87). The interaction of ANT with CerS6 has 
been reported to be involved in ceramide-induced preven-
tion of permeability transition pore opening and calcium ac-
cumulation in mitochondria of oligodendrocytes (62). It 
remains to be determined whether the interaction of ce-
ramide-enriched membrane domains with transporters and 
channels in the inner mitochondrial membrane, OMM, or 
MAM is part of a regulatory cascade or module to affect en-
ergy and calcium homeostasis in mitochondria.
There is some discrepancy in which VDAC isoform is 
more critical for regulation of intracellular ATP, which is 
likely to be cell-type specific (51, 52). Most recently, excess 
elevation of ceramide has been shown to induce mitophagy, 
suggesting that the physiological function of ceramide, as 
discussed in our study, requires limitation of its concentra-
tion at mitochondria (88, 89). While ATP levels observed in 
our study are consistent with CAT-regulated ATP release 
under normal physiological conditions, several studies have 
shown that, under pathophysiological conditions, reduction 
pseudocolored in red (scale bars = 20 m; n = 4; *P < 0.05). G: Coimmunoprecipitation analysis of the VDAC1-tubulin complex in control 
(Con) and ceramide-depleted (FB1-treated) HEK293T cells. Input is protein after solubilization of mitochondria with 1% digitonin used for 
incubation with anti--tubulin mouse IgG or nonspecific mouse IgG (control). Output is protein eluted after pull-down with anti-mouse IgG 
gel beads and immunoblotted using anti-VDAC1 rabbit IgG. Ceramide depletion was achieved by incubation of cells for 60 h with 3 M FB1. 
Lane 1, input control cells; lane 2, input FB1-treated cells; lane 3, output control IgG with nontreated cells; lane 4, output anti--tubulin IgG 
with nontreated cells; lane 5, output control IgG with FB1-treated cells; lane 6, output anti--tubulin IgG with FB1-treated cells. H, I: ATP 
levels in WT (H) or control (Con) (I) and nSMase2-deficient (H) or FB1-treated (I) astrocytes (n = 4 independent cell cultures; *P < 0.05; 
**P < 0.01).
Fig. 10. Hypothetical mechanism of VDAC1 closure by CAT in CEMAMs. A: Elevated cytosolic tubulin levels 
due to increased microtubule disassembly/reduced assembly lead to association of tubulin with ceramide in 
CEMAM-resident CATs that wrap around mitochondria and block VDAC1-mediated ADP/ATP transport be-
tween mitochondria and the cytosol. Lack of ATP leads to inactivation of motor proteins and mitochondria 
stop moving (STOP mode). B: When microtubules extend to the periphery, cytosolic (free) tubulin concen-
tration is low, VDAC1 unblocked, and ATP available to drive mitochondria transport along microtubules (GO 
mode). Higher ceramide levels facilitate ATP deprivation and the STOP mode, while low ceramide levels fa-
vor ATP release and the GO mode. This leads to higher mitochondrial motility in nSMase2-deficient or FB1-
treated astrocytes. C, D: Potential arrangement and ceramide binding of  tubulin dimers interacting with 
VDAC1 in the OMM. Note that binding of -tubulin to ceramide in CATs is likely to be mediated by protein 
domains defined as cluster 2 from molecular modeling shown in supplemental Fig. S3C, D. Also note that 
complex formation with VDAC1 is likely to be mediated by the dimer with -tubulin reaching into the VDAC1 
pore with its C-terminal tail (CTT).
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of ATP levels are concurrent with decreased mitochondrial 
motility and increased fragmentation (44, 90–92). The con-
tribution of excess ceramide to this mitotoxicity is likely to 
include additional mechanisms, which will be explored in 
future studies. Likewise, there is discrepancy in the litera-
ture with respect to the effect of FB1 on mitochondria. FB1 
has been shown to protect cells from apoptosis by reducing 
the effect of ceramide on mitochondria, but it has also been 
described to inhibit mitochondrial complex I and induce 
cell death (93–95). This discrepancy may be due to differ-
ent FB1 concentrations and incubation times, as well as the 
limitation that, in many of the previous studies, the effect of 
FB1 was not compared with any other effects of ceramide 
depletion by enzyme inhibition or deficiency in ceramide 
metabolism. In our study, the results from the effect of FB1 
are consistent with those from nSMase2 deficiency, support-
ing the conclusion that reduction of ceramide generation 
leads to increase of ATP levels and, potentially, other bene-
ficial effects, such as resistance to mitotoxic insults.
While reduction of ceramide levels is likely to be protec-
tive to mitochondria, excess ceramide elevation is common 
to several neurodegenerative diseases. We and others have 
shown that A activates nSMase2 and increases ceramide 
levels in astrocytes and other neural cells (3, 4, 96–99). It is 
reasonable to assume that mitotoxicity of ceramide involves 
a cascade of cooperating mechanisms depending on its con-
centration and distribution. Therefore, inhibiting ceramide 
biosynthesis or downregulating nSMase2 may protect mito-
chondria from A-induced damage, although definition of 
the exact mechanism will still require additional research. 
One should also keep in mind that our experiments were 
performed with cells in vitro. Any in vitro model can only 
approximate the in vivo process and is subject to experi-
mental limitations, particularly when attempting to emu-
late the conditions in the aging human brain. Despite this 
limitation, preventing ceramide elevation emerges as 
a promising strategy for therapy of AD and other neuro-
degenerative diseases and our results will help define a 
common function of ceramide in the regulation and dys-
regulation of mitochondria in normal and pathological 
brain, respectively.
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